Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents

被引:0
|
作者
Luo, Y
Rockow-Magnone, SK
Joseph, MK
Bradner, J
Butler, CC
Tahir, SK
Han, EKH
Ng, SC
Severin, JM
Gubbins, EJ
Reilly, RM
Rueter, A
Simmer, RL
Holzman, TF
Giranda, VL
机构
[1] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 47S AP9A, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 4N6 AP9, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Adv Technol Pharmaceut Prod Div, Dept 4MD AP10, Abbott Pk, IL 60064 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
G2; abrogation; Chkl; UCN01; staurosporine; chemotherapy sensitization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chkl is a checkpoint gene that is activated after DNA damage, It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage. Methods: We treated 184B5 cell line and its E6 transformed cell lines with adriamycin in the presence of staurosporine or UCNO1 and examined induced a p53 and p21 response as well as a G1 arrest in 184B5 cells, but not in its E6 transformed cells. Staurosporine or UCNO1 abrogated the G2 arrest induced by adriamycin in both cell lines. In addition staurosporine or UCNO1 specifically sensitized p52 incompetent cells to adriamycin. Conclusion: G2/M checkpoint abrogators can potentially enhance the cytotoxic effect of conventional chemotherapeutic reagents specifically to tumor cells.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 50 条
  • [1] UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation
    Sugiyama, K
    Shimizu, M
    Akiyama, T
    Tamaoki, T
    Yamaguchi, K
    Takahashi, R
    Eastman, A
    Akinaga, S
    INTERNATIONAL JOURNAL OF CANCER, 2000, 85 (05) : 703 - 709
  • [2] UCN-01 selectively enhances mitomycin C-cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation.
    Sugiyama, K
    Shimizu, M
    Akiyama, T
    Tamaoki, T
    Inoue, K
    Yamaguchi, K
    Takahashi, R
    Eastman, A
    Akinaga, S
    CLINICAL CANCER RESEARCH, 1999, 5 : 3753S - 3754S
  • [3] Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation
    Minemoto, Y
    Uchida, S
    Ohtsubo, M
    Shimura, M
    Sasagawa, T
    Hirata, M
    Nakagama, H
    Ishizaka, Y
    Yamashita, K
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 412 (01) : 13 - 19
  • [4] p53 Regulation of G2 checkpoint is retinoblastoma protein dependent
    Flatt, PM
    Tang, LJ
    Scatena, CD
    Szak, ST
    Pietenpol, JA
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (12) : 4210 - 4223
  • [5] Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents
    Lang, Fengchao
    Cornwell, James A.
    Kaur, Karambir
    Elmogazy, Omar
    Zhang, Wei
    Zhang, Meili
    Song, Hua
    Sun, Zhonghe
    Wu, Xiaolin
    Aladjem, Mirit, I
    Aregger, Michael
    Cappell, Steven D.
    Yang, Chunzhang
    NEURO-ONCOLOGY, 2024, 26 (06) : 1083 - 1096
  • [6] A dysfunctional G2 cell cycle checkpoint pathway in p53 mutant glioma cells.
    Walters, D
    Wetmore, LA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : U202 - U202
  • [7] Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator
    Wang, YL
    Li, J
    Booher, RN
    Kraker, A
    Lawrence, T
    Leopold, WR
    Sun, Y
    CANCER RESEARCH, 2001, 61 (22) : 8211 - 8217
  • [8] G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
    N Bucher
    C D Britten
    British Journal of Cancer, 2008, 98 : 523 - 528
  • [9] G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
    Bucher, N.
    Britten, C. D.
    BRITISH JOURNAL OF CANCER, 2008, 98 (03) : 523 - 528
  • [10] p53 regulates a G2 checkpoint through cyclin B1
    Innocente, SA
    Abrahamson, JLA
    Cogswell, JP
    Lee, JM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) : 2147 - 2152